Current Issue

View Larger Image

Past Issues Adlink Subscription Visit Our Publisher

ADVERTISEMENT



Top Keywords




GENpoll: Dec 16, 2011

User Fees for Biosimilars

Do you agree with FDA’s new framework covering user fees and performance goals for biosimilar developers?

Yes
 
  50.0%
Somewhat
 
  16.7%
No
 
  16.7%
Undecided
 
  16.7%

Suggest a Poll
« More Polls » « View Results »

FDA is holding a public meeting to fine-tune the fees biosimilar developers must pay for the federal fiscal years 2013 through 2017. It is hoped that steps to define user-generated funding for the biosimilar approval program will aid FDA in fulfilling its of creating a biosimilars pathway that balances innovation and consumer interests. FDA envisions creating four categories of user fees. Biosimilar product development (BPD) fees of 10% of the fee established for a drug under PDUFA will be collected, starting when sponsors submit an IND or meet with FDA and for every year after until the sponsor submits a marketing application or ends participation in BPD. Second, at marketing application submission, sponsors would pay fees equal to those established under PDUFA minus the BPD fees paid. The final two fee categories are establishment fees and product fees, both of which would be equal to those paid by drug developers under PDUFA. Do you think this structure will work?

Related content

GEN News Highlights

MORE RELATED GEN NEWS HIGHLIGHTS

Insight & Intelligence™

MORE RELATED INSIGHT & INTELLIGENCE™

GEN Articles

MORE RELATED GEN ARTICLES

BLOG biotech

MORE RELATED BLOG BIOTECH

GEN Podcasts

MORE RELATED GEN PODCASTS

New Products

MORE RELATED NEW PRODUCTS

Best of the Web

MORE RELATED BEST OF THE WEB

GEN Polls

MORE RELATED GEN POLLS

Subscription center

BACK TO TOP

GEN MAGAZINE

Genetic Engineering & Biotechnology News (GEN) has retained its position as the most widely read biotechnology publication around the globe since its launch in 1981. Published 21 times a year and with additional exclusive editorial content online, GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.

Subscribe
e-NEWSLETTERS

Add GEN to your Inbox! Subscribe today to our complimentary e-newsletters and stay abreast of the latest biotech news and trends. Click the magnifying glass icon next to a newsletter title to view a sample.
 

All fields are required
Email
Confirm Email
First Name
Last Name
Organization
E-Alert Format
 
 
  Sign Up

ADVERTISEMENT

GEN webinars

« View All Webinars »

ADVERTISEMENT

ADVERTISEMENT

GENpoll

Funding Early-Stage Companies

How much do you think newly established funds will succeed in helping startups?

Suggest a Poll
« More »     « View Results »     « Poll Archive »